Last reviewed · How we verify
Rivaroxaban or Warfarin
At a glance
| Generic name | Rivaroxaban or Warfarin |
|---|---|
| Sponsor | Fujita Health University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves (PHASE3)
- LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus (PHASE2)
- Rivaroxaban in Idiopathic Membranous Nephropathy (PHASE4)
- Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis (PHASE4)
- Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy (PHASE4)
- Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF (NA)
- Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control
- Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rivaroxaban or Warfarin CI brief — competitive landscape report
- Rivaroxaban or Warfarin updates RSS · CI watch RSS
- Fujita Health University portfolio CI